Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging

Molecular Cancer Therapeutics

Volumn 6, Issue 6, 2007, Pages 1701-1708

  Oyajobi, Babatunde O ^a,b,c,f   Muñoz, Steve ^a   Kakonen, Rami ^a,g   Williams, Paul J ^a   Gupta, Anjana ^a   Wideman, Christi L ^a   Story, Beryl ^a   Grubbs, Barry ^a   Armstrong, Allison ^e   Dougall, William C ^e   Garrett, I Ross ^d   Mundy, Gregory R ^a,b,c,h  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b CTRC Institute for Drug Development   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

^d OsteoScreen   (United States)

^e AMGEN INC   (United States)

^f Mays Cancer Center at UT Health San Antonio   (United States)

^g Pharmatest Services Ltd   (Finland)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; GREEN FLUORESCENT PROTEIN; PROTEASOME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CAMERA; CELL HOMING; CONTROLLED STUDY; DRUG EFFECT; FEMALE; ILLUMINATION; IMAGING; MOUSE; MOUSE STRAIN; MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; FLUORESCENCE; GREEN FLUORESCENT PROTEINS; MICE; MULTIPLE MYELOMA;

EID: 34250749795     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0121     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Oyajobi BO, Mundy GR. Pathophysiology of myeloma bone disease. In: Garhton G, Durie BGM, Samson DS, editors. Multiple myeloma and related diseases. 2nd ed. London: Arnold; 2004. p 74-8.
3. Kyle RA, Rajkumar SV. Multiple myeloma. N Eng J Med 2004;351:1860-73.
4. Cavo M, Baccarani M. Changing landscape of myeloma therapy. N Eng J Med 2006;354:1076-8.
5. Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology 2004;231:11-23.
6. Radl J, Croese JW, Zurcher C, van den Enden-Vieveen MM, de Leeuw AM. Animal model of human disease: multiple myeloma. Am J Pathol 1998;132:593-7.
7. Garrett IR, Dallas S, Radl J, Mundy GR. A murine model of myeloma bone disease. Bone 1997;20:515-20.
8. Dallas SL, Garrett IR, Oyajobi BO, et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999;93:1697-706.
9. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1a on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003;102:311-9.
10. van den Akker TW, Radl J, Franken-Postma E, Hagemeijer A. Cytogenetic findings in mouse multiple myeloma and Waldenstrom's macroglobulinaemia. Cancer Genet Cytogenet 1996;86:156-61.
11. Zhu D, Van Arkel C, King CA, et al. Immunoglobulin Vh gene sequence analysis of spontaneous murine immunoglobulin-secreting B-cell tumours with clinical features of human disease. Immunology 1998;93:162-70.
12. Bakkus MH, Asosingh K, Vanderkerken K, et al. Myeloma isotype-switch variants in the murine 5T myeloma model: evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour. Leukemia 2001;15:1127-32.
13. Vanderkerken K, Goes E, De Raeve H, Radl J, Van Camp B. Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography. Br J Cancer 1996;73:1463-5.
14. Vanderkerken K, De Raeve H, Goes E, et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 1997;76:451-60.
15. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 2001;98:5181-6.
16. Yang M, Baranov E, Jiang P, et al. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci U S A 2000;97:1206-11.
17. Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, Clezardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001;16:2027-34.
18. Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol 2006;3:374-87.
19. Kinsella T, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996;7:1405-13.
20. Steff AM, Fortin M, Arguin C, Hugo P. Detection of a decrease in green fluorescent protein fluorescence for the monitoring of cell death: an assay amenable to high-throughput screening technologies. Cytometry 2001;45:237-43.
21. Mitsiades CS, Mitsiades NS, Bronson RT, et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 2003;63:6689-96.